TIDMSYNC
RNS Number : 0208G
Syncona Limited
10 November 2022
Syncona Limited
Anaveon presents updated data from Phase I/II study of
ANV419
10 November 2022
Syncona Ltd, a leading healthcare company focused on founding,
building and funding a portfolio of global leaders in life science,
notes that its portfolio company, Anaveon AG ("Anaveon"), a
clinical-stage immuno-oncology company, has announced updated
clinical data from the ongoing Phase I/II study of ANV419 in
patients with solid tumours, at the Society for Immunotherapy of
Cancer (SITC) 37th Annual Meeting, being held from November 8-12,
2022, at the Boston Convention and Exhibition Center in Boston,
MA.
Key highlights are as follows:
-- In the ongoing study, 29 patients with different cancers
progressing after standard therapy have been dosed across ten dose
cohorts
-- ANV419 generally well tolerated across dose cohorts up to and
including 243 ug/kg, underlining the favourable safety and
tolerability profile of the drug
-- Further encouraging efficacy data with 66% of patients
achieving at least disease stabilisation at ANV419 doses >=108
ug/kg
-- Importantly, the data shows deepening of tumour response with continued ANV419
-- Anaveon has initiated Phase I/II studies to demonstrate the
efficacy of ANV419 in metastatic melanoma and multiple myeloma
Pre-clinical data for ANV419 in combination with checkpoint
inhibitors was also presented, building on data presented at the
European Society for Medical Oncology (ESMO) Congress 2022 in
September.
The full text announcement is contained below and can be viewed
on the company's website , along with the accompanying posters. The
abstracts are available on the SITC website .
Martin Murphy, Chief Executive Officer and Chair of Syncona
Investment Management Limited, said: "This early data presented by
Anaveon at SITC further underlines the potential of ANV419 as a
therapy for patients suffering from a range of solid tumours. We
are pleased to see the drug continue to present a strong safety and
tolerability profile. Critically for patients, the data is showing
deepening of tumour response with continued ANV419. We look forward
to seeing further data from Anaveon as it initiates Phase I/II
trials in metastatic melanoma and multiple myeloma and are excited
by the potential of this drug to deliver for patients in real
need."
[S]
Copies of this press release and other corporate information can
be found on the company website at: www.synconaltd.com
Enquiries
Syncona Ltd
Annabel Clark / Fergus Witt
Tel: +44 (0) 20 3981 7940
FTI Consulting
Ben Atwell / Natalie Garland-Collins / Julia Bradshaw / Tim
Stamper
Tel: +44 (0) 20 3727 1000
About Syncona
Syncona's purpose is to invest to extend and enhance human life.
We do this by founding and building companies to deliver
transformational treatments to patients in areas of high unmet
need.
Our strategy is to found, build and fund companies around
exceptional science to create a diversified portfolio of 15-20
globally leading healthcare businesses for the benefit of all our
stakeholders. We focus on developing treatments for patients by
working in close partnership with world-class academic founders and
management teams. Our balance sheet underpins our strategy enabling
us to take a long-term view as we look to improve the lives of
patients with no or poor treatment options, build sustainable life
science companies and deliver strong risk-adjusted returns to
shareholders.
About Anaveon
Anaveon is a clinical stage, biopharmaceutical company, based in
Switzerland, that develops biologics to modulate the function of
cytokines and provide substantial therapeutic benefit to cancer
patients. Our vision is to develop novel immune therapies
benefiting patients suffering from a wide variety of diseases with
immune pathology. For further information please visit the
Company's website at: www.anaveon.com .
Anaveon presents updated data from the Phase I/II study of
ANV419 during the SITC Annual Meeting
- ANV419 delivers high dose IL-2 to patients with good safety
and tolerability -
- Deepening of tumor response with continued ANV419 -
Basel, November 10 , 2022 - Anaveon, a clinical stage,
immuno-oncology company, today announced updated clinical data from
the ongoing Phase I study of ANV419 in patients with solid tumors
at the Society for Immunotherapy of Cancer (SITC) 37th Annual
Meeting, being held from November 8-12, 2022, at the Boston
Convention and Exhibition Center in Boston, MA.
In the ongoing study, 29 patients in 10 dosing cohorts with
different cancers progressing after standard therapy, received
ANV419 monotherapy once every 14 days at doses up to 364 ug /kg in
two-week cycles as an intravenous infusion over 15 minutes. ANV419
is a powerful and selective IL-2 agonist, which has been
specifically designed to enable the delivery of high dose IL-2 to
patients, with a favourable safety and tolerability profile.
In the study, ANV419 was generally well tolerated, and al l drug
related events were manageable, reversible, and responsive to
supportive care therapy. The most common drug related AEs were low
grade (G1 or G2) fever, chills, vomiting and fatigue. No patients
have withdrawn from the study due to AEs and no dose limiting
toxicities were observed up to and including 243 ug /kg.
In this heavily pre-treated population, 5 patients continue to
receive treatment. At ANV419 doses >=108 ug/kg, 66% of patients
achieved at least disease stabilization (9 SD, 1 PR) . One patient
who continues ANV419 treatment, has a confirmed Partial Response
(as per RECISTv1.1) with 31% tumor shrinkage after 2 weeks of
ANV419 and a sustained and deepening response of 56% shrinkage at 6
cycles (12 weeks) of ANV419.
Pharmacodynamic evaluation of ANV419 on day 4 post-dosing (cycle
1 and 2) showed a selective and dose dependent proliferation of
CD8+ T and NK cells, with a lower increase of proliferating Tregs.
ANV419 half-life increases up to 28 hours with increasing doses and
ANV419 concentration is overall stable between cycles.
Anaveon has initiated Ph I/II studies to demonstrate efficacy of
ANV419 in metastatic melanoma and multiple myeloma.
Dr. Elena Garralda at the Hospital Universitari Vall d'Hebron in
Barcelona, and lead investigator on the study said, "These early
clinical data are encouraging and I believe ANV419 has the
potential to become an important component of therapy for patients
with cancer."
Preclinical data for ANV419 in combination with checkpoint
inhibitors that builds on the data presented at the European
Society for Medical Oncology (ESMO) Congress 2022 in September were
also presented at SITC. These continue to demonstrate broad
activity of ANV419 on effector cells, supporting the initiation of
Phase II studies assessing ANV419 treatment in indications in which
CD8 T cells and NK cells are involved in tumor resolution as well
as supporting combination studies with checkpoint inhibitors and
treatments acting through antibody-dependent cellular
cytotoxicity.
"It is very exciting to see the continued safety and
tolerability of ANV419 at higher doses, demonstrating the ability
of ANV419 to deliver high molar equivalents of IL-2 in a tolerable
and convenient way. Importantly, tumor response continues to
deepen," added Christoph Bucher, MD, Chief Medical Officer of
Anaveon. " We have initiated our first Phase II trial,
investigating the efficacy of ANV419 in patients with cutaneous
melanoma and we look forward to starting our Phase II study in
Multiple Myeloma, whilst also broadening our pipeline with
therapies that we expect will be effective as both standalone and
combination therapies."
Abstracts are available on the SITC website and the accompanying
posters will be available in the publications section of Anaveon's
website .
Details of the poster presentations are:
Title: Phase I dose escalation study in patients with advanced
solid tumors with ANV419, a novel fusion protein selective for
IL-2R<BETA>/<GAMMA>
Authors : Christoph Bucher, MD; Guzman Alonso, Dr; Juanita
Lopez; Emiliano Calvo; Markus Joerger, MD; Vicky Sanchez Perez, MD;
Elena Corral, MD; Daniela Di Blasi, PhD; Kirsten Richter, PhD;
Christoph Huber, PhD; Julie Mouton; Silvio Costanzo; Sangeeta
Jethwa, MD; Elena Garralda, MD; Heinz Läubli, MD PhD
Presenter: Daniela Di Blasi, PhD
Abstract Number: 631
Date & Time: Thursday, November 10, 2022 from 9 a.m. to 9
p.m. EST
Title: ANV419 is a novel CD122-biased IL-2/anti-IL-2 fusion
protein showing increased efficacy in combination with checkpoint
inhibitors and treatments acting through antibody dependent
cellular cytotoxicity
Authors : Christoph Huber, PhD; Kirsten Richter, PhD; Laetitia
Petersen; Nicole Egli; Patrizia Murer, PhD
Presenter: Christoph Huber, PhD
Abstract Number: 1099
Date & Time: Thursday, November 10, 2022 from 9 a.m. to 9
p.m. EST
Anaveon is undertaking a Phase I/II study to evaluate the
safety, dosing and clinical activity of its lead program, ANV419, a
powerful and selective interleukin-2 (IL-2) agonist in patients
with solid tumors. The Company is pursuing multiple parallel Phase
II programs in order to explore the full therapeutic potential of
ANV419. In addition, Anaveon continues its work in developing
follow-on compounds to expand on the success of ANV419 by
delivering the IL-2 agonist to tumor fighting cells and thus expand
the therapeutic potential into less immunogenic tumors. Alongside
this, the Company is building on its cytokine engineering expertise
with preclinical-stage programs harnessing the power of cytokines
for therapeutic purposes.
S
Enquiries
JW Communications
Julia Wilson
Email: Julia.wilson@anaveon.com
Tel: +44 (0)7818 430877
About Anaveon:
Anaveon is a clinical stage, biopharmaceutical company, based in
Switzerland, that develops biologics to modulate the function of
cytokines and provide substantial therapeutic benefit to cancer
patients. Our vision is to develop novel immune therapies
benefiting patients suffering from a wide variety of diseases with
immune pathology. For further information please visit the
Company's website at: www.anaveon.com .
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
PFUBDBDBRDBDGDG
(END) Dow Jones Newswires
November 10, 2022 09:05 ET (14:05 GMT)
Syncona (LSE:SYNC)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Syncona (LSE:SYNC)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024